CoVac-1
- Generic Name
- CoVac-1
- Drug Type
- Biotech
- Background
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein. It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)) and aims to induce broad T-cell immunity.
A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults
Phase 1
Completed
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- Interventions
- Biological: Saline Placebo
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 47
- Registration Number
- NCT05693272
- Locations
- 🇨🇦
Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada
🇨🇦Diex Recherche Joliette Inc., Joliette, Quebec, Canada
🇨🇦DIEX Recherche Victoriaville, Victoriaville, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath